Autologous Anti-CLL-1-CAR T-lymphocytes KITE-222

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) C-type-lectin-like molecule-1 (CLL-1; CLL1; C-type lectin domain family 12 member A; CLEC12A), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CLL-1-CAR T-lymphocytes KITE-222 specifically target and bind to CLL-1-expressing tumor cells. This induces selective toxicity in tumor cells that express the CLL-1 antigen. CLL-1, a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed in leukemic stem cells (LSCs) and plays an important role in disease progression and relapse for myeloid malignancies.

**Synonyms:** - Autologous Anti-CLL-1-CAR T-cells KITE-222 - Autologous Anti-CLL1 CAR T Cells KITE-222 - Autologous Anti-CLL1-CAR-T Cells KITE-222 - KITE 222 - KITE-222 - KITE222